MGB Biopharma
Snodland
About MGB Biopharma
MGB Biopharma Limited is a biopharmaceutical company established to develop a completely new class of anti-infective medicines based upon compounds which are DNA Minor Groove Binders (MGB) The company has an exceptionally experienced team from both pharma and biotech sectors and is dedicating its focus initially to the development of small molecules with specific antibacterial efffects against resistant bacteria By selecting a new class of antibacterial, the company believes the novel mode of action should prove to be very potent against bacteria as these target organisms will lack any inherent resistance, unlike that typically facing new drugs which are the result of modifications from existing classes of drugs used to treat bacterial infection
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $18.4M
- Last round: Series Unknown (Aug 2019)
- Website: mgb-biopharma.com
- Phone: +44 (014) 122-8623
Industries & Categories
Biotechnology, Health Care, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/mgb-biopharma-122168 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.